Mission BioOur Newest Instrument: Unlocking the Ground Truth of Cancer Through Response, Relapse & RemissionBy Charlie Silver, CEO and Founder of Mission BioOct 29, 2020Oct 29, 2020
Mission BioMission Bio Raises $70M to Accelerate Biomarker Discovery and Drug DevelopmentBy Charlie Silver, CEO & Co-founder of Mission BioAug 13, 2020Aug 13, 2020
Mission BioHow Cancer Research Has Progressed Thanks to Research Gains with TapestriBy Darrin Crisitello, CCO Mission BioJul 15, 2020Jul 15, 2020
Mission BioMission Bio and Agilent Technologies Partner to Advance Precision MedicineBy Darrin Crisitello, Chief Commercial Officer, Mission BioApr 24, 2020Apr 24, 2020
Mission BioMD Anderson Analyzes AML With Tapestri, Unveiling New Therapy Response PatternsBy Charlie Silver, Co-Founder & CEO, Mission BioApr 20, 2020Apr 20, 2020
Mission BioHow Stanford is Using Tapestri to Understand Cancer RelapseBy Charlie Silver, Co-Founder & CEO, Mission BioMar 26, 20201Mar 26, 20201
Mission BioToday Marks Another Mission Bio Milestone Towards Beating Cancer by 2030Charlie Silver, Co-Founder & CEO, Mission BioNov 6, 2019Nov 6, 2019
Mission BioTapestri Platform, the First to Track the Full Scope Genomics of CancerBy Charlie Silver, CEO of Mission BioAug 22, 2019Aug 22, 2019
Mission BioMission Bio and Onconova Take Single-Cell One Step Closer to the ClinicBy Darrin Crisitello, CCO Mission BioAug 15, 2019Aug 15, 2019
Mission BioRewiring Cancer Care in China with Single-Cell GenomicsBy Darrin Crisitello, Chief Commercial Officer, Mission BioJul 10, 2019Jul 10, 2019
